n/a
Article Publish Status: FREE
Abstract Title:

Resveratrol enhances chemosensitivity of renal cell carcinoma to paclitaxel.

Abstract Source:

Front Biosci (Landmark Ed). 2019 Jun 1 ;24:1452-1461. Epub 2019 Jun 1. PMID: 31136990

Abstract Author(s):

Ke Ying Jie, Chen Ling Wei, Zhou Min, Guo Jia Ping, Wang Ying, Zheng Dan, Zhong Sen

Article Affiliation:

Ke Ying Jie

Abstract:

By restraining proliferation and promoting apoptosis, resveratrol (RES) has anti-tumor effect in various cancers. Here, we examine whether RES exerts similar effect in drug-resistant renal cell carcinoma (RCC). To this end, Caki-1 cells derived from renal carcinoma are subjected to escalated doses of paclitaxel (PTX) to produce the PTX resistant Caki-1cells. Both Caki-1 and Caki-cells are sensitive to PTX, in a dose dependent manner. RES, dose-dependently, suppresses the expression of survivin, a molecular biomarker of cancer and a member of the inhibitor of apoptosis (IAP) family and its co-administration with PTX inhibits the effect of this drug on cell viability. To decipher whether survivin expressed by cancer cells is involved in rendering cells PTX sensitive, survivin is overexpressed. This dramatically counteracts the effects of RES on cell survival in the presence of PTX. Furthermore, decrease of survivin by inhibition of PI3K/AKT pathway significantly inhibits the effect of PTX in Caki-1cells. These data show that RES increases the sensitivity of PTX resistant renal cells to drug treatment.

Study Type : In Vitro Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.